Seaport TherapeuticsSPTX
Recorded

Seaport Therapeutics 2026 Stifel Healthcare Conference

Review the key takeaways and the transcript of this earnings call.

Period 2026Duration31 minParticipants4

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Paul MatteisAnalyst

All right. Thanks very much. Happy to be here with the Seaport Therapeutics team. We'll do Q&A and keep it conversational, but maybe I'll start off by throwing it over to Lauren White, CFO, to kick it off, give a quick overview of Seaport, maybe talk about the next data events coming up in 2027 and 2028, and then we'll dive into it.

Lauren WhiteCFO

Sure. Sounds good. Awesome. Thank you.

Lauren WhiteCFO

Big thank you, Paul, for having us here today, and a warm welcome to those in the audience and on the webcast. We are going to be sharing some forward-looking statements today, which are based on our expectations and beliefs, and we encourage you to look at our SEC filings. I'd like to start by taking a step back and just looking bigger picture at the opportunity. There's over 1 billion people living globally with mental illness. Over 300 million suffer from depression, and over 300 million suffer from anxiety. There's hardly a family that's not touched. When you look at the existing treatments that are out there, they're successes. They're deemed commercially viable, they generate billions of dollars in sales, and more importantly, they help millions of patients, but they all have limitations that have held them back.

Lauren WhiteCFO

Seaport Therapeutics is a neuropsychiatry company that is focused on turning the tide of mental health and focusing on bringing new therapies to patients. We are a clinically validated platform. We have got a robust pipeline of three programs that we will talk about today, and we have got an experienced team that is really focused on how we execute our trials. Our lead program, GlyphAllo, is currently in a phase IIb potential registration-enabling study in MDD. Our second program, GlyphAgo, we recently shared key proof-of-concept data, and we just dosed our patient in a phase IIa trial in generalized anxiety disorder. Our third program, Glyph2BLSD, is in preclinical development. While still early, given all of the excitement in the psychedelic space, the key thesis there is, can you get the benefit of a psychedelic without the trip?

Lauren WhiteCFO

We at Seaport are focused on programs that are clinically validated, meaning they have generated human efficacy, but they were held back by some sort of a limitation that we are able to address with our Glyph platform. Glyph is a lymphatic targeting prodrug platform that is able to overcome issues such as poor oral bioavailability, liver-related AEs, and other side effects. The great thing is that every time we Glyph a molecule, we generate new composition of matter IP. We have got a seasoned leadership team with a track record of success, both in bringing new medicines to patients and in delivering on successful business outcomes. You are probably aware that our CEO, Daphne Zohar, and our board chair, Steve Paul, founded and led Karuna. We are actually taking a similar approach at Seaport that Karuna took.

Lauren WhiteCFO

For example, at Karuna, they knew that xanomeline worked, but it was sitting on a shelf due to GI tolerability issues. The team was able to overcome those issues with the invention of KarXT, now called COBENFY. Looking ahead, we believe our cash runway is $403 million, and that will take us into 2029, which is what we have currently guided to, and we get through three really exciting clinical readouts. We get through our top-line readout of our current trial in GlyphAllo, BUOY-1. That is in the first half of 2027. Then we move into our second program, GlyphAgo. We get our phase IIa readout in early 2028, and our phase II/III potentially registration-enabling trial at the end of 2028. Paul, we are really looking forward to the path ahead over the next few years.

Paul MatteisAnalyst

Great. Thanks, Lauren. Appreciate it. Maybe starting with GlyphAllo, I lived through every moment of Sage from IPO to the acquisition, and the program in MDD definitely had some super high ups and some downs as well. I guess, how do you guys make sense of the totality of the data there, and your confidence that that is not just a PPD drug, it is really an MDD mechanism too?

Tony LoebelCMO and President of Clinical Development

I wonder if we can start by just saying a few words about the Glyph platform and bring a little bit more detail to that. Michael, do you want to just go us that, expand on that a bit?

Michael ChenChief Scientific Officer

Sure. With the Glyph technology, which as Lauren mentioned, is a lymphatic targeted technology, we are able to change the PK profile of drugs like allopregnanolone, very relevant to the experience that Sage had with the original IV product, ZULRESSO, which clearly had efficacy in postpartum depression and had some advantages that Tony will speak on. Overall, Glyph is a technology platform based on dietary fat, so it allows us to cloak a molecule as if it were a fat, which changes the way that it's absorbed by the body, allowing us to bypass first-pass metabolism at the level of the liver. This is important for allowing drugs, for example, allopregnanolone, that were only previously available as an IV form to be delivered orally. For example, in clinical trials, we've shown that GlyphAllo is able to achieve comparable exposures as that IV allopregnanolone, but with once-daily oral dosing.

Michael ChenChief Scientific Officer

As Lauren mentioned, we also recently announced top-line data showing clinical validation for our second program, GlyphAgo, which again validates an aspect of the Glyph technology. I think this is all relevant as we look back towards the Sage experience into having a differentiated program with GlyphAllo, not only in the molecule, but also how we design and execute clinical trials to show that molecule's potential efficacy.

Paul MatteisAnalyst

Okay. So yeah, maybe going back to the zuranolone data.

Tony LoebelCMO and President of Clinical Development

Yeah. I think Michael sort of hit some of the high points there. GlyphAllo or Glyph allopregnanolone is a neuroactive steroid that's an endogenous or naturally occurring compound, that has, based on Sage and other relevant third-party trials, antidepressant, anti-anxiety, and sleep-promoting effects, that already are well-established and therefore de-risk the molecule in terms of our own use of it in clinical development. Sage did bring allopregnanolone to the clinic in the form of IV brexanolone, and that's important because it reflects the fact, as Michael noted, that allopregnanolone by itself is not orally bioavailable. In fact, about 90%-95% of it is chewed up by the liver if administered orally, and there just isn't sufficient PK, sufficient exposure to have therapeutic effects at the level of the brain after straight oral ingestion.

Tony LoebelCMO and President of Clinical Development

The 60-hour continuous IV infusion of IV allopregnanolone, on the other hand, was very effective in the treatment of patients, women with postpartum depression. You saw this rapid onset of effect consistently across their trials, and you saw that there was substantial improvement that was durable and lasted after the infusion ended, all the way through several weeks, up to about four weeks post-infusion. Sage also brought forward zuranolone, which is a synthetic analog of allopregnanolone, in an attempt to enhance the oral bioavailability of the neurosteroid mechanism, and succeeded at extending the half-life of zuranolone and also creating a once-daily orally bioavailable agent. That was very helpful, and it was introduced into MDD studies.

Tony LoebelCMO and President of Clinical Development

The good news is that most of those studies, five out of six of those trials, as you know, Paul, succeeded in hitting the primary endpoint, which is at two weeks of treatment exposure in people with MDD. So, very good track record of that molecule in terms of major depressive disorder and major depressive episode. The problem is, and the bad news was, that the drug did not hit at six weeks, which was the minimum that FDA really expected for a drug in MDD to show at least some appropriate sustained or durable effects at around six to eight weeks.

Tony LoebelCMO and President of Clinical Development

The point being that Sage did not treat patients beyond two weeks, and therefore, arguably, it was a bit unsurprising if you have patients off treatment for a month before assessing them at the week six endpoint, albeit a secondary endpoint, there's not going to be a lot of separation. That is one of the major lessons learned from that zuranolone program. We think that the problem with zuranolone is not so much the biology or the pharmacology of the drug, but clinical design aspects and construction. We've clearly incorporated those lessons into our Seaport development program for GlyphAllo, Glyph allopregnanolone, and in the currently ongoing MDD trial, patients with major depressive episode, we are treating for a full six weeks, once daily, at night, at bedtime, and we'll be assessing at six weeks using the HAMD-17 endpoint.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.

View the full transcript with Pro

Other earnings calls that day

View calls from this day